)
Evolent Health (EVH) investor relations material
Evolent Health Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $725.4M, up 11% sequentially and 51.3% year over year; Adjusted EBITDA was $34.3M, down from $39.0M a year earlier, while GAAP net loss narrowed to $23.6M.
MER improved sequentially to 93% from 95%; growth reflected Performance Suite contract launches, oncology expansion, and continued customer additions.
- Q2 2026 revenue up to $653M, guidance raised, and oncology partnership announced.EVH
Q2 2026 - Revenue up 2.6% to $496.2M, net loss narrows, and new contracts support future growth.EVH
Q1 2026 - Proxy covers director elections, auditor ratification, compensation, and equity plan amendment.EVH
Proxy filing - Director elections, auditor ratification, and executive pay up for vote at June 2026 meeting.EVH
Proxy filing - Strong pipeline, conservative guidance, and focus on profitability drive growth outlook.EVH
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 2026 guidance projects 30–33% revenue growth and margin expansion, led by new contracts.EVH
Q4 2025 - Stable specialty trends, new protections, and divestiture proceeds drive growth and deleveraging.EVH
Piper Sandler 37th Annual Healthcare Conference - AI-driven specialty care and recent acquisitions fuel growth toward a $300M EBITDA target.EVH
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - Q1 2025 revenue fell and losses widened, but new agreements and guidance reaffirm growth prospects.EVH
Q1 2025
)
)
)
)
)
)
)
)